Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | LDHB | P07195 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22188467 | 0.87 | BCL2 (0.42) | BCL2BCL2L1HTR2ACALM1CYP3A4 | |
| Bicarbonate SCHEMBL22188469 | 0.81 | LDHA (0.43) | BCL2BCL2L1CNR2GPR55LDHA | |
| Oxalic Acid SCHEMBL22188503 | 0.80 | LDHA (0.42) | BCL2BCL2L1CNR2GPR55LDHA | |
| SCHEMBL10886157 | 0.80 | BCL2 (0.42) | BCL2BCL2L1HTR2ACALM1CYP3A4 | |
| SCHEMBL28493010 | 0.80 | BCL2 (0.42) | BCL2BCL2L1HTR2ACALM1CYP3A4 | |
| SCHEMBL31402366 | 0.80 | BCL2 (0.42) | BCL2BCL2L1HTR2ACALM1CYP3A4 | |
| SCHEMBL7904072 | 0.79 | BCL2 (0.45) | BCL2BCL2L1HTR2ACALM1CYP3A4 | |
| SCHEMBL10845366 | 0.78 | HTR2A (0.41) | BCL2BCL2L1HTR2ACALM1CYP3A4 | |
| Malonic Acid SCHEMBL22188497 | 0.78 | PTGDR2 (0.41) | BCL2BCL2L1CNR2GPR55LDHA | |
| Maleic Acid SCHEMBL22188519 | 0.77 | HRH1 (0.43) | BCL2BCL2L1CYP2D6CYP2C19LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363876-B1 | GLUCOCORTICOID RECEPTOR MODULATORS | KAROBIO AB (SE) | 2009-07-29 | — | — | EP | disclosed |
| US-6583180-B2 | Antidiabetic agents | ABBOTT LABORATORIES | 2003-06-24 | — | — | US | disclosed |
| US-20020156311-A1 | Glucocorticoid receptor modulators | KARO BIO AB (SE) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156311-A1 | Glucocorticoid receptor modulators | NR3C1, NR5A1, NR3C2 | BCL2 4573/4885BCL2L1 4035/4885HTR2A 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.